No connection

Search Results

Earnings Score 45 Bullish

Genmab Reports Robust Q1 Sales for DARZALEX Cancer Therapy

Apr 14, 2026 17:17 UTC
GMAB
Short term

Genmab A/S announced global net trade sales of nearly $4 billion for its multiple myeloma treatment, DARZALEX, in the first quarter of 2026. The results highlight continued strong demand across both domestic and international markets.

  • Global net trade sales of $3.964 billion
  • US market contribution of $2.208 billion
  • International market contribution of $1.756 billion
  • Royalties earned via Johnson & Johnson partnership
  • Stock price increase of 3.21% to $29.10

Genmab A/S (GMAB) has reported strong first-quarter performance for DARZALEX (daratumumab), with global net trade sales reaching $3.964 billion. The cancer therapy, which is marketed through a partnership with Johnson & Johnson, continues to be a primary revenue driver for the company. Under the existing licensing agreement, Genmab receives royalties on the worldwide sales of the drug. DARZALEX is used to treat multiple myeloma and is available in both subcutaneous and intravenous formulations to accommodate patient needs and treatment preferences. The sales breakdown shows a strong presence in the United States, which accounted for $2.208 billion of the total. International markets contributed the remaining $1.756 billion, demonstrating the therapy's broad global reach and adoption. Following the announcement, Genmab shares rose 3.21% to $29.10 on the Nasdaq. The robust sales figures underscore the commercial viability of the therapy and provide a stable, high-volume royalty stream for Genmab as it continues its operations in the oncology space.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Related Articles

Score 45 Bullish

ASML Options Market Signals 6% Volatility Ahead of Q1 Earnings

Apr 14, 21:06

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile